Business
Hardman & Co Research Report: Development Progress
Hardman & Co Research Report: Development Progress.
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n \nRNS Number : 9359P Allergy Therapeutics PLC 24 February 2016 \n\n \nHardman & Co issues research report on Allergy Therapeutics\n \nDevelopment progress: AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. It has an underlying profitable and cash generative business despite its lead product being available only on a 'Named Patient' basis. However, protocols agreed with EU and US regulators are in place to get Pollinex Quattro approved as a biological. The US opportunity is enormous and only two players have short-course treatments. There is a valuation mis-match between AGY and its peers, which either have no growth or little marketing experience, which provides scope for considerable upside towards our risk-adjusted DCF valuation of 89p per share.\n \nPlease click here for the full report:\n \nhttp://www.hardmanandco.com/docs/default-source/company-docs/allergy-therapeutics-documents/24-02-16-development-progress\n \n\n\n\n\nTo contact us: \nHardman & Co\n11/12 Tokenhouse Yard \nLondon\nEC2R 7AS\n\n\nContact: Dr Martin Hall [email protected] \nTelephone: +44 20 7929 3399\nFollow us on Twitter @HardmanandCo\n \n \n\n\n\n\n \nwww.hardmanandco.com \n \nAbout Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.\n \nHardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.\n \nOur research is provided for the use of the professional investment community, market counterparties and soph...